Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60.

View in: PubMed

subject areas

Adolescent
Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Disability Evaluation
Disease-Free Survival
Double-Blind Method
Female
Gadolinium
Humans
Immunosuppressive Agents
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Natalizumab
Odds Ratio
Retrospective Studies
Young Adult

authors with profiles

Dusan Stefoski